2023
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile
Grajales V, Contieri R, Tan W, Flores M, Schultz M, Pinochet R, Bustamante A, Kamat A, Fernández M. Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile. Bladder Cancer 2023, 9: 327-334. PMID: 38994240, PMCID: PMC11165921, DOI: 10.3233/blc-230047.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBacillus Calmette-GuerinBacillus Calmette-Guerin treatmentHR-NMIBC patientsInvasive bladder cancerOncological outcomesHigh riskBladder cancerHigh-risk non-muscle invasive bladder cancerPatients treated with bacillus Calmette-GuerinAdjuvant bacillus Calmette-GuerinBacillus Calmette-Guerin instillationsFull doseFD groupMultivariate Cox regression modelCalculate survival estimatesReduced-dose regimensMedian follow-upRecurrence free rateKaplan-Meier methodReduced toxicity profileCox regression modelsHR-NMIBCStratify patientsRetrospective studyImpact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin
Contieri R, Grajales V, Tan W, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras‐Gonzalez G, Guo C, Navai N, Dinney C, Kamat A. Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin. BJU International 2023, 133: 63-70. PMID: 37442564, PMCID: PMC10787034, DOI: 10.1111/bju.16127.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinCancer-specific mortalityCompeting-risk regression analysisCohort of patientsOncological outcomesFood and Drug AdministrationHG recurrenceAssociated with adverse oncologic outcomesHigh-gradeImpact of ageInstitutional review board-approved retrospective studyBacillus Calmette-Guerin instillationsIntravesical BCGCumulative incidence of progressionAdverse oncologic outcomesIncidence of progressionAssociation of advanced ageUnited States Food and Drug AdministrationStates Food and Drug AdministrationCumulative incidence methodPredictors of progressionStudy's primary outcomeBCG instillationRegression analysis
2021
Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Zhao H, Chan V, Castellani D, Chan E, Ong W, Peng Q, Moschini M, Krajewski W, Pradere B, Ng C, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan W, Kelly J, Shariat S, Witjes J, Teoh J. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Frontiers In Surgery 2021, 8: 775527. PMID: 34888347, PMCID: PMC8649716, DOI: 10.3389/fsurg.2021.775527.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerHigh-risk non-muscle invasive bladder cancerInvasive bladder cancerOncological outcomesSafety profileBladder cancerAdverse eventsMeta-analysisBacillus Calmette-Guerin instillationsHigh-risk NMIBC patientsIntravesical bacillus Calmette-GuerinMeta-analysis of clinical studiesBCG maintenance therapySystematic reviewMonths recurrence rateCochrane RoB toolCertainty of evidenceRisk of biasComprehensive literature searchBCG shortageChemotherapy maintenanceNMIBC patientsBCG treatmentMaintenance therapyRecurrence rateP0773 Intravesical chemohyperthermia versus bacillus calmette-guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: A systematic review and meta-analysis
Zhao H, Chan V, Castellani D, Chan E, Ong W, Peng Q, Moschini M, Krajewski W, Pradere B, Ng C, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan W, Kelly J, Shariat S, Witjes J, Teoh J. P0773 Intravesical chemohyperthermia versus bacillus calmette-guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: A systematic review and meta-analysis. European Urology 2021, 79: s1068-s1069. DOI: 10.1016/s0302-2838(21)01148-9.Peer-Reviewed Original ResearchHigh-risk non-muscle invasive bladder cancerNon-muscle invasive bladder cancerBacillus Calmette-Guerin instillationsInvasive bladder cancerSystematic reviewBladder cancerMeta-analysis